ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO
→ ADC Therapeutics, which last month closed its monster $303 million E round, is joining forces with Freenome, a biotech developing a diagnostic for early cancer detection through a routine blood draw. ADC will use Freenome’s platform to identify patients who are most likely to respond to treatment with its experimental drug, loncastuximab tesirine, which is currently in a pivotal Phase II in patients with relapsed or refractory diffuse large B-cell lymphoma. ADC hopes to file for an approval in the second half of 2020.
→ Amid ongoing protests in Hong Kong and an escalating US-China trade war, Shanghai Henlius Biotech is forging ahead with its planned IPO on the HKEX with a goal to fetch as much as $600 million, Bloomberg reported. The company — a joint venture of Fosun and Henlius focused initially on biosimilars — began engaging investors today. Its first approved product is a copycat of Rituxan/MabThera, with Herceptin and Humira knockoffs in the pipeline.
→ Four months ago, metabolic and endocrine disorder-focused Lipocine $LPCN sued Clarus Therapeutics for its recently approved oral testosterone replacement therapy, Jatenzo, alleging the latter has infringed on six of its US patents. On Monday, Clarus disclosed that Lipocine was not seeking preliminary injunctive relief against Clarus, even in the event that Clarus launches Jatenzo. Meanwhile, a trial date for the dispute between Clarus and Lipocine has been set for August 24, 2020 in the United States District Court for the District of Delaware.